USE OF NKP46 FOR PREVENTING DIABETES

Ofer Mandelboim; Angel Porgador; Yaakov Naparstek; Chamutal Gur

USE OF NKP46 FOR PREVENTING DIABETES

Ofer Mandelboim (Inventor), Angel Porgador (Inventor), Yaakov Naparstek (Inventor), Chamutal Gur (Inventor)

The Shraga Segal Department of Microbiology, Immunology and Genetics

Ben-Gurion University of the Negev

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original language	American English
Patent number	US2012076753
IPC	A61P 37/ 02 A I
Priority date	18/03/10
State	Published - 29 Mar 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{508a2451b6c444edabf2c44c20c3cf8c,

title = "USE OF NKP46 FOR PREVENTING DIABETES",

abstract = "The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.",

author = "Ofer Mandelboim and Angel Porgador and Yaakov Naparstek and Chamutal Gur",

year = "2012",

month = mar,

day = "29",

language = "American English",

type = "Patent",

note = "US2012076753; A61P 37/ 02 A I",

}

TY - PAT

T1 - USE OF NKP46 FOR PREVENTING DIABETES

AU - Mandelboim, Ofer

AU - Porgador, Angel

AU - Naparstek, Yaakov

AU - Gur, Chamutal

PY - 2012/3/29

Y1 - 2012/3/29

N2 - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

AB - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

M3 - Patent

M1 - US2012076753

ER -

USE OF NKP46 FOR PREVENTING DIABETES

Abstract

UN SDGs

Fingerprint

Cite this